MGAT4B and melanoma: Our investigation further revealed that melanoma patients with both the BRAFV600E mutation and elevated MGAT4B levels have significantly worse survival outcomes compared to those with only the BRAFV600E mutation (logrank test P value 0.0152) (SI Appendix, Fig. S8D).